ArticleDiscover oncology2025
Assessing causal associations between TNF-related apoptosis-inducing ligand, vascular endothelial growth factor and colon cancer: a Mendelian-randomization study.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundObservational studies have shown that TNF-related apoptosis-inducing ligand (TRAIL) levels and vascular endothelial growth factor (VEGF) levels are associated with colon cancer risk, and TRAIL antagonizes VEGF-induced tumor angiogenesis. We aim to determine whether there is a causal relationship between TRAIL/VEGF levels and colon cancer by Mendelian randomization analysis.
methodsGenome-wide association studies (GWAS) of 21,758 individuals of European ancestry were conducted to identify single nucleotide polymorphisms (SNPs) associated with TRAIL/VEGF. MR-Egger regression, heterogeneity test, pleiotropy test and leave-one-out sensitivity tests were used for sensitivity analysis, in addition to inverse variance weighting (IVW) as the main Mendelian-randomization (MR) analysis method.
resultsUnivariate MR analysis using IVW indicated an inverse association between genetically predicted TRAIL levels and colon cancer risk (OR = 0.805, 95%CI = 0.681-0.953, P = 0.011), while VEGF levels showed a positive association (OR = 1.337, 95%CI = 1.163-1.536, P < 0.001). In addition, the MR Steiger test showed that the effect of TRAIL/VEGF levels on colon cancer were correct causality (P < 0.001). In multivariate MR analysis, TRAIL levels had an independent causal effect on colon cancer risk after controlling for VEGF levels (OR = 0.802, P = 0.002); likewise, the causal effect of VEGF levels on colon cancer risk remained after controlling for TRAIL levels (OR = 1.328, P < 0.001).
conclusionsThere was a inverse association between genetic variants in TRAIL levels and colon cancer risk, but a positive association between genetic variants in VEGF levels and colon cancer risk. Further research is needed to explore the mechanisms behind this putative causal relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.